Literature DB >> 2318254

Induction of interleukin 6 by human and murine recombinant interleukin 1 in mice.

C Libert1, P Brouckaert, A Shaw, W Fiers.   

Abstract

Interleukin (IL) 6 is a pleistropic cytokine with activities, among others, on immune cells, hematopoietic precursor cells and hepatocytes. We have investigated the kinetics and amplitude of its in vivo induction in mice after injection of four different IL 1 species as well as murine (m) and human (h) tumor necrosis factor (TNF) and bacterial lipopolysaccharide (LPS) using a sensitive bioassay on 7TD1 cells to measure the IL 6 concentrations. Recombinant mIL 1 beta, administered as a single i.v. injection in mice, induced the appearance of IL 6 in the plasma with peak levels observed after 2 h. A dose-response correlation was found between serum IL 6 levels and injected IL 1 alpha concentrations at 3 and 8 h after the injection. We then compared the ability of h/mIL 1 alpha, h/mIL 1 beta, h/mTNF and LPS to induce IL 6 in mice. We found: (a) LPS is the most potent inducer of IL 6; (b) 3 h after injection, the four IL 1 preparations had induced IL 6 levels comparable with the IL 6 levels observed after TNF injection; (c) high doses of mIL 1, alpha or beta, but not hIL 1, resulted in a high IL 6 level persisting for over 8 h. We conclude that IL 1 is a potent inducer of IL 6 in vivo and that no major differences are observed between the four IL 1 preparations, as evaluated at 3 h after the injection. However, mIL 1 alpha and mIL 1 beta, in contrast to hIL 1 alpha and hIL 1 beta, induced a sustained IL 6 level over a longer time period. This pattern of prolonged IL 6 induction is even much more pronounced after mTNF injection, but not after hTNF injection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2318254     DOI: 10.1002/eji.1830200333

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

1.  Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma.

Authors:  Pierre L Triozzi; Wayne Aldrich; Arun Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-25       Impact factor: 4.799

2.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

3.  Mechanisms and significance of the increased brain uptake of tryptophan.

Authors:  Natalie R Lenard; Adrian J Dunn
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

4.  Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant.

Authors:  Jan Tavernier; Sarah Gerlo; Bram Van Den Eeckhout; Lien Van Hoecke; Elianne Burg; Sandra Van Lint; Frank Peelman; Niko Kley; Gilles Uzé; Xavier Saelens
Journal:  NPJ Vaccines       Date:  2020-07-23       Impact factor: 7.344

5.  Antipyretic Effects of Citral and Possible Mechanisms of Action.

Authors:  Maycon T Emílio-Silva; Clarissa M D Mota; Clélia A Hiruma-Lima; José Antunes-Rodrigues; Evelin C Cárnio; Luiz G S Branco
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

6.  Sepsis attenuates the anabolic response to skeletal muscle contraction.

Authors:  Jennifer L Steiner; Charles H Lang
Journal:  Shock       Date:  2015-04       Impact factor: 3.454

7.  Plasma cytokines after thermal injury and their relationship to infection.

Authors:  A C Drost; D G Burleson; W G Cioffi; A D Mason; B A Pruitt
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

8.  Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice.

Authors:  T Tsujinaka; J Fujita; C Ebisui; M Yano; E Kominami; K Suzuki; K Tanaka; A Katsume; Y Ohsugi; H Shiozaki; M Monden
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

9.  In vivo activation of human immunodeficiency virus type 1 long terminal repeat by UV type A (UV-A) light plus psoralen and UV-B light in the skin of transgenic mice.

Authors:  J D Morrey; S M Bourn; T D Bunch; M K Jackson; R W Sidwell; L R Barrows; R A Daynes; C A Rosen
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

10.  Gene regulation system of vasopressin and corticotropin-releasing hormone.

Authors:  Masanori Yoshida
Journal:  Gene Regul Syst Bio       Date:  2008-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.